SerwisPolskiego Towarzystwa Onkologii Klinicznej

ESMO Virtual Congress.

11 września 2020

Bezpłatna rejestracja dla członków ESMO ( https://ptok.pl/czlonkostwo/porozumienie_esmo_ptok ) na tegoroczny ESMO Virtual Congress:

https://www.esmo.org/meetings/esmo-virtual-congress-2020/registration?hit=mail-gen&utm_campaign=ESMO%202020&utm_medium=email&_hsmi=94780408&_hsenc=p2ANqtz-9daLOfckmw77Dw484pTl5JUmBcvCFAbsDReabjrRVsUKR77qKHr_X9kYOvRG5wZXPHKs0ARWaOTi86TjtXYMUtVMGhRA&utm_content=94780408&utm_source=hs_email

Informacje o programie naukowym kongresu:

» Further advances of targeted therapies in NSCLC:
- ADAURA: Adjuvant osimertinib in EGFR-mutated NSCLC after resection (LBA1)
- CROWN: Lorlatinib in 1st line ALK-positive advanced NSCLC (LBA2)

» Adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer:
- monarchE: Abemaciclib in high risk early breast cancer (LBA5)
- PALASE: Adjuvant palbociclib in early breast cancer (LBA12)
- Randomized preoperative window of opportunity study with CDK4/6 inhibitor in early breast cancer (161O)

» Blocking PI3K/AKT signalling pathway in mCRPC:
- IPATential150: Ipatasertib plus abiraterone metastatic castration-resistant prostate cancer (LBA4)

» Immunotherapy advances in TNBC:
- IMpassion031: Neoadjuvant atezolizumab plus chemotherapy in early TNBC (LBA11)
- IMpassion130: Final OS analysis of atezolizumab plus nab-paclitaxel in previously untreated advanced TNBC (LBA16)

» Advances in postoperative radiotherapy for NSCLC:
- Lung ART: Post-operative conformal radiotherapy in completely resected NSCLC and mediastinal N2 involvement (LBA3)

» Combination of targeted therapy and immunotherapy:
- LEAP-005: Lenvatinib plus pembrolizumab in previously treated advanced solid tumours (LBA41)
- LEAP-004: Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1(L1) therapy (LBA44)

https://www.esmo.org/meetings/esmo-virtual-congress-2020/programme?hit=mail-gen&utm_campaign=ESMO%202020&utm_medium=email&_hsenc=p2ANqtz-9XO6MfkYK7SR_wTGVtQYUyKQY1l7pzABm24gLPeb_zBckrJPtKv_b6mDvCx9QaWvvoKbxq3Vc5zOV7TJ_A9tZHVSGynA&_hsmi=94780408&utm_content=94780408&utm_source=hs_email&hsCtaTracking=2f98c83e-8b92-4299-b77f-40e755fca25b%7C95276f36-9fc5-4a65-8297-4fd9c669763b